ESTRO 2025 - Abstract Book

S1133

Clinical – Head & neck

ESTRO 2025

Conclusion: We demonstrate that baseline dual planning and application of NTCP modelling may facilitate selection of patients for DART. The NTCP-modelled benefit from DART-enabled PTV margin reduction varies between patients, however an individual’s benefit from DART appears maintained throughout treatment. Use of NTCP thresholds may have utility for patient selection for future adaptive trials. Prospective outcome data confirming modelled toxicity benefit are required.

Keywords: DART, PTV, adaptive

References: [1] Morgan HE, Sher DJ. Adaptive radiotherapy for head and neck cancer. Cancers Head Neck 2020;5:1. [2] Beetz I et al. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric and clinical factors. Radiotherapy and Oncology 2012;105:101–6. [3] Christianen MEMC et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational study. Radiotherapy and Oncology 2012;105:107–14.